Showing 7721-7730 of 9722 results for "".
- News You Can Use: AARS Extends Deadline for Research Grant Applicationshttps://practicaldermatology.com/news/news-you-can-use-aars-extends-deadline-for-research-grant-applications-1/2461672/The American Acne and Rosacea Society is extending the deadline to apply for an AARS Clinical Research Award ($10K) or the AARS Research Scholar Award ($75K). The new application deadline is Friday, April 28, 2023. Applications are available online at acneandrosacea.org/
- Melanoma Research Alliance, Bimini Bay Outfitters Join Forces to Advance Researchhttps://practicaldermatology.com/news/melanoma-research-alliance-bimini-bay-outfitters-join-forces-to-advance-research/2461667/The Melanoma Research Alliance and Bimini Bay Outfitters, a leader in high-performance outdoor apparel, are partnering to accelerate research into melanoma and promote sun safety among outdoor enthusiasts. Alongside a series of educational content rolling out from both organizatio
- ASLMS News: BTL Unveils EXIONhttps://practicaldermatology.com/news/aslms-news-btl-unveils-exion/2461661/Just in time for their 30th anniversary, BTL is launching EXION, a multiplatform device featuring micro-needling RF, a non-invasive face and body applicator for skin laxity, and the EMFEMME 360 applicator for intimate health. EXION can also be combined with EMFACE to treat bot
- Prior Immunotherapy May Predict Response to PD-1 Checkpoint Blockadehttps://practicaldermatology.com/news/prior-immunotherapy-may-predict-response-to-pd-1-checkpoint-blockade/2461655/Responses to PD-1 checkpoint blockade in patients with advanced melanoma depend on whether or not they had previously received CTLA-4 blockade as well as other factors, new research suggests. Their findings, based on analysis of seven data sets generated over the past decade, which incl
- Cutera CEO, Executive Chairman Axedhttps://practicaldermatology.com/news/shake-up-at-cutera-shareholder-ceo-look-to-reconstitute-board/2461654/Cutera, Inc. has fired CEO David Mowry and Executive Chairman Daniel Plants for alleged violations of their employment contracts. Sheila Hopkins has been appointed as interim CEO and the search for a permanent replacement is underway. Plants and Mowry called for a Sp
- It's Official: April Is the Coolest Month of the Yearhttps://practicaldermatology.com/news/its-official-april-is-the-coolest-month-of-the-year/2461642/April 2023 marks the first-ever CoolMonth, according to Allergan Aesthetics, an AbbVie company and the parent company of CoolSculpting Elite. Why April? A survey revealed 85% of people have a season in which they begin to think more about getting rid of stubborn body fat
- Researchers Discover Anti-Aging Potential in an Invasive Weedhttps://practicaldermatology.com/news/researchers-discover-anti-aging-potential-in-an-invasive-weed/2461638/The fruit of the cocklebur plant, which grows worldwide and is often considered a noxious weed, has antioxidant and anti-inflammatory components that could make it useful as a skin protectant, according to new research
- FDA Approves Humira Biosimilar Hyrimozhttps://practicaldermatology.com/news/fda-approves-humira-biosimilar-hyrimoz/2461636/The FDA approved a citrate-free high-concentration formulation (HCF) of Hyrimoz (adalimumab-adaz; Sandoz) injection, a biosimilar to Humira (adalimumab). The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference medicine, Humira, in
- EON Robotic Body Contouring Device Receives Additional FDA Clearance for Back and Thighshttps://practicaldermatology.com/news/eon-robotic-body-contouring-device-receives-additional-fda-clearance-for-back-and-thighs/2461629/EON Smarter Body Contouring has received FDA clearance for the back and thighs—the third FDA clearance for EON. The device was previously FDA-cleared for clinical providers to treat patients' full abdomen and flanks. Parent company Dominion Aesthetic Technologies describe
- Eye on OX40 in AD: Rocatinlimab Performs Well in Two Phase 2 Trialshttps://practicaldermatology.com/news/eye-on-ox40-in-ad-rocatinlimab-performs-well-in-two-phase-2-trials/2461617/OX40 is considered a new potential treatment target in atopic dermatitis (AD), and two new studies of the investigational anti-OX40 monoclonal antibody rocatinlimab may add weight to the evidence. Rocatinlimab inhibits and reduces the number of OX40+ pathogenic T cells responsible